TMED Stock News Trimedyne Inc (TMED) 0.1031 07/26/2014 16:53

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Trimedyne Inc (TMED) 0.1031 $TMED

Trimedyne Reports Its Financial Results for the Quarter and Six Months Ended March 31, 2014
Marketwire - Fri May 16, 8:15AM CDT
TRIMEDYNE, INC. (OTCBB: TMED) today reported its financial results for the quarter and six month period ended March 31, 2014.

Trimedyne Reports Its Financial Results for the Quarter Ended December 31, 2013
Marketwire - Wed Feb 19, 8:15AM CST
TRIMEDYNE, INC. (OTCQB: TMED) (OTCBB: TMED) today reported its financial results for the first quarter of its fiscal year.

Trimedyne Reports Financial Results for the Quarter and Fiscal Year Ended September 30, 2013
Marketwire - Wed Jan 15, 7:01AM CST
TRIMEDYNE, INC. (OTCBB: TMED) (OTCQB: TMED) reported revenues of $5,989,000 for the fiscal year ended September 30, 2012, a 1.5% decrease from revenues of $6,080,000 for the prior fiscal year. The decrease was primarily due to the decrease in domestic Laser sales combined with the delaying of shipments of Fibers, Needles and Switch Tips resulting from the relocation to our new manufacturing facility in Irvine, California.

Global Medical Laser Systems Market Report 2013-2018: Global Aesthetics Laser Market Poised to Grow
M2 - Thu Sep 05, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/np483b/medical_laser#summary) has announced the addition of the "Medical Laser Systems - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Medical Laser Systems in US$ Million by the following Product Segments: - Surgical Lasers - Aesthetic Lasers - Ophthalmic Lasers - Diagnostic Lasers - Therapeutic Lasers - Accessories & Services. The report profiles 139 companies including many key and niche players such as: - AngioDynamics Inc. - Bausch & Lomb Incorporated - BIOLASE Inc. - Biolitec AG - Cardiogenesis Corporation - Carl Zeiss Meditec AG - Coherent Inc. - Cutera Inc - Cynosure Inc. - Palomar Medical Technologies Inc. - Dornier Medtech GmbH - Ellex Medical Lasers Limited - IRIDEX Corporation - Lumenis Ltd - Lynton Lasers Ltd - Nidek Co Ltd. - Novartis AG - PhotoMedex Inc. - Radiancy Inc. - Spectranetics Corporation - Syneron Medical Ltd. - Candela Corporation - Topcon Corporation - Trimedyne Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Market Trends And Issues 3. Medical Laser Systems: Product Overview 4. Product Introductions/Approvals 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 139 (including Divisions/Subsidiaries - 175) - The United States (87) - Canada (3) - Japan (6) - Europe (64) - - France (6) - - Germany (28) - - The United Kingdom (6) - - Italy (8) - - Spain (1) - - Rest of Europe (15) - Asia-Pacific (Excluding Japan) (12) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/np...er#summary

Trimedyne Reports Its Financial Results for the Quarter and Nine Months Ended June 30, 2013
ACCESSWIRE - Thu Aug 22, 8:07AM CDT
Irvine, CA, August 22, 2013 - (Accesswire) - TRIMEDYNE, INC. (OTCQB: TMED) today reported its financial results for the quarter and nine months ended June 30, 2013.

Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
PR Newswire - Fri Feb 01, 8:00AM CST
TRIMEDYNE, INC. (OTCBB "TMED" reported revenues of $6,080,000 for the fiscal year ended September 30, 2012, a 9% decrease from revenues of $6,656,000 for the prior fiscal year. The decrease in revenues was largely due to a decrease in sales of Lasers, partially offset by an increase in sales of Fibers, Needles and Tips.

John C. Chiu, M.D., Has Agreed to Be Medical Director and Chief Investigator of the Clinical Trials of Hyperdyne, Inc., a Subsidiary Being Created by Trimedyne
Marketwire - Mon Jan 07, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED), today announced that John C. Chiu, M.D., an internationally respected neurosurgeon who practices in Newbury Park, CA, has agreed to serve as Medical Director and Chief Investigator of the three (3) randomized, controlled clinical trials to be conducted, subject to receiving funding, by Orthodyne, Inc., ("Orthodyne" , a subsidiary being a organized by Trimedyne.

Professor Anthony J. Costello, M.D. Agrees to Conduct Pre-Clinical Testing and Lead the Clinical Trials in Asia and Southeast Asia of Urodyne, Inc. and Hyperdyne, Inc., Subsidiaries Being Created by Trimedyne
Marketwire - Thu Dec 27, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED) today announced Professor Anthony J. Costello, M.D., Head of the Department of Urology of the Royal Melbourne Hospital of the University of Melbourne (Australia), will serve as Lead Investigator in Asia and Southeast Asia, subject to their receiving funding, of the three (3), 300 patient, randomized, controlled clinical trials of Urodyne, Inc. ("Urodyne" in the treatment of Benign Prostatic Hyperplasia or BPH (commonly called an enlarged prostate) and the treatment of Urinary Incontinence and Fecal Incontinence and, subject to their receiving funding, the two (2), 300 patient randomized, controlled clinical trials of Hyperdyne, Inc. ("Hyperdyne" in the treatment of Uncontrolled Hypertension (high blood pressure not controllable by drugs) in Endoscopic and Percutaneous (balloon angioplasty-like) Procedures. He will select the medical centers to participate in the clinical trials in these areas of the world and train the physicians of the medical centers in the co

Graham M. Watson, M.D., Agrees to Serve as Lead Investigator of the Clinical Trials in Europe and Middle East of Urodyne, Inc. and Hyperdyne, Inc., Subsidiaries Trimedyne Plans to Create
Marketwire - Fri Dec 21, 8:00AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED), today announced Graham M. Watson, M.D., has agreed to serve as Lead Investigator in Europe and the Middle East, subject to receiving funding, of the three (3), 300 patient, randomized clinical trials of Urodyne, Inc. ("Urodyne" to treat Benign Prostatic Hyperplasia or BPH, commonly referred to as an "Enlarged Prostate," urinary incontinence and fecal incontinence in Endoscopic Procedures and, subject to receiving funding, the two (2) 300 patient randomized, controlled clinical trials of Hyperdyne, Inc. ("Hyperdyne" to treat Hypertension not controllable by drugs, one in Endoscopic Procedures and the other in Percutaneous (angioplasty-like) Procedures.

Robert S. Cowles, III, M.D. Joins Urodyne, Inc. and Hyperdyne, Inc., Two Subsidiaries Trimedyne Plans to Organize, as Co-Chairman and Medical Director
Marketwire - Thu Dec 20, 8:01AM CST
TRIMEDYNE, INC. ("Trimedyne" (OTCBB: TMED) today announced that Robert S. Cowles, III, M.D. has agreed to serve as Co-Chairman with Dr. Marvin P. Loeb of the Boards of Directors and as Medical Director of Urodyne, Inc. ("Urodyne" and Hyperdyne, Inc. ("Hyperdyne" , two subsidiaries Trimedyne plans to organize. (See Trimedyne's Press Release of November 28, 2012).

Robert S. Cowles, III, M.D. Joins Trimedyne as Its Medical Director
Marketwire - Wed Dec 19, 8:01AM CST
TRIMEDYNE, INC. (OTCBB: TMED), today announced that Robert S. Cowles, III, M.D. has agreed to serve as Medical Director of Trimedyne. He will review Trimedyne's new technologies and advise Trimedyne on the design of the clinical trials to be conducted, subject to receipt of funding, by the seven (7) subsidiaries Trimedyne plans to organize (See Trimedyne's Press Release dated November 28, 2012).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 24

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 37

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Würk's Bryte AI Targets Payroll's Costly Friction Points

Updated Category News Views 83

Payroll mistakes are the sort of paper cuts that suddenly turn into a hospital bill for an employer. Würk’s Nov. 19 launch of Bryte AI goes straight at that ugly reality in cannabis, beverage alcohol, and other heavily regulated workplaces, where a bad time entry, missed document, or misunderstood policy can create a far more expensive mess than ordinary office...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 37

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
MedStar's Same-Day Test Puts Stroke Drugs on Notice

Updated Category News Views 25

A five-hour lab result can matter more than another glossy precision-medicine slogan. MedStar Health says it is using same-day genetic testing for patients with ischemic stroke, giving clinicians information before discharge that previously often arrived more than a week later. That is a practical change, not science-fiction wallpaper: a treatment decision gets made while...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 95

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 123

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Action1's 3,688% Growth Puts Patching on Investor Maps

Updated Category News Views 52

Patch Management Finally Gets Some Respect Nothing makes a security buyer flinch faster than a machine carrying a known vulnerability for weeks, and Action1 has plainly found that nerve. The Houston-based autonomous endpoint management company says it was the fastest-growing endpoint management vendor on Deloitte's 2026 Technology Fast 500 for the second consecutive year,...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 99

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading

Top 5 Most Recently Viewed Articles

A.O. Smith Sells 81% of China Arm to CPE: Key Takeaways

Updated Category News Views 372

When a major player like A.O. Smith decides to offload a piece of its business, folks tend to sit up and pay attention. This isn't just some run-of-the-mill shuffling. A.O. Smith has inked a deal with CPE to hand over an 81% stake in its China business. What does this transaction bring to the table and who stands to gain? Broken Down for the Curious Investor The numbers...

Continue Reading
NCCN Expands Global Influence at Historical Cancer Forum

Updated Category News Views 177

NCCN’s Involvement in Global Cancer Initiatives The National Comprehensive Cancer Network is actively participating in a progressive forum uniting various organizations dedicated to cancer control. This gathering includes representatives from approximately 75 nations, marking a significant milestone in international collaboration. Focus of the Cancer Planners Forum The...

Continue Reading
eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 85

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
Exploring the Surge in Options Trading with GE Vernova Insights

Updated Category News Views 67

Understanding the Current Options Trading Landscape of GE Vernova Recently, financial sectors have shown strong bullish interest in GE Vernova. Our detailed analysis indicates a noteworthy trend in options trading for GE Vernova (GEV), where we've identified an impressive number of unusual trading activities. Digging deeper into the specifics, we observed that 66% of...

Continue Reading
Volatus Aerospace: Leading the Charge in Aerial Innovations

Updated Category News Views 310

Volatus Aerospace: Leading the Charge in Aerial Innovations Volatus Aerospace Inc. (TSXV: FLT, OTCQX: TAKOF, Frankfurt: ABB) continues to excel as a frontrunner in sovereign aerial solutions. The company recently shared an impressive corporate update, showcasing its robust financial standing, an increasing array of international contracts, and a commitment to align with...

Continue Reading